Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 256


Long-term kidney function, proteinuria, and associated risks among HIV-infected and uninfected men.

Palella FJ Jr, Li X, Gupta SK, Estrella MM, Phair JP, Margolick JB, Detels R, Kingsley L, Jacobson LP.

AIDS. 2018 Jun 19;32(10):1247-1256. doi: 10.1097/QAD.0000000000001807.


Frailty and Circulating Markers of Inflammation in HIV+ and HIV- Men in the Multicenter AIDS Cohort Study.

Margolick JB, Bream JH, Martínez-Maza O, Lopez J, Li X, Phair JP, Koletar SL, Jacobson LP.

J Acquir Immune Defic Syndr. 2017 Apr 1;74(4):407-417. doi: 10.1097/QAI.0000000000001261.


Associations between antiretroviral use and subclinical coronary atherosclerosis.

Thomas GP, Li X, Post WS, Jacobson LP, Witt MD, Brown TT, Kingsley LA, Phair JP, Palella FJ Jr.

AIDS. 2016 Oct 23;30(16):2477-2486.


Data on serologic inflammatory biomarkers assessed using multiplex assays and host characteristics in the Multicenter AIDS Cohort Study (MACS).

McKay HS, Bream JH, Margolick JB, Martínez-Maza O, Magpantay LI, Phair JP, Rinaldo CR, Abraham AG, Jacobson LP.

Data Brief. 2016 Aug 16;9:262-70. doi: 10.1016/j.dib.2016.08.019. eCollection 2016 Dec.


Host factors associated with serologic inflammatory markers assessed using multiplex assays.

McKay HS, Bream JH, Margolick JB, Martínez-Maza O, Phair JP, Rinaldo CR, Abraham AG, Jacobson LP.

Cytokine. 2016 Sep;85:71-9. doi: 10.1016/j.cyto.2016.05.016. Epub 2016 Jun 10.


Brief Report: Highly Active Antiretroviral Therapy Mitigates Liver Disease in HIV Infection.

Price JC, Seaberg EC, Phair JP, Witt MD, Koletar SL, Thio CL.

J Acquir Immune Defic Syndr. 2016 Jul 1;72(3):319-23. doi: 10.1097/QAI.0000000000000981.


Spontaneous Clearance of the Hepatitis C Virus Among Men Who Have Sex With Men.

Seaberg EC, Witt MD, Jacobson LP, Detels R, Rinaldo CR, Margolick JB, Young S, Phair JP, Thio CL.

Clin Infect Dis. 2015 Nov 1;61(9):1381-8. doi: 10.1093/cid/civ562. Epub 2015 Jul 14.


Differences in hepatitis C virus prevalence and clearance by mode of acquisition among men who have sex with men.

Seaberg EC, Witt MD, Jacobson LP, Detels R, Rinaldo CR, Young S, Phair JP, Thio CL.

J Viral Hepat. 2014 Oct;21(10):696-705. doi: 10.1111/jvh.12198. Epub 2013 Nov 7.


Long-term predictive value of the Framingham Risk Score for Stroke in HIV-positive vs HIV-negative men.

Mateen FJ, Post WS, Sacktor N, Abraham AG, Becker JT, Smith BR, Detels R, Martin E, Phair JP, Shinohara RT; Multicenter AIDS Cohort Study (MACS) Investigators.

Neurology. 2013 Dec 10;81(24):2094-102. doi: 10.1212/01.wnl.0000437296.97946.73. Epub 2013 Nov 8.


Age, comorbidities, and AIDS predict a frailty phenotype in men who have sex with men.

Althoff KN, Jacobson LP, Cranston RD, Detels R, Phair JP, Li X, Margolick JB; Multicenter AIDS Cohort Study (MACS).

J Gerontol A Biol Sci Med Sci. 2014 Feb;69(2):189-98. doi: 10.1093/gerona/glt148. Epub 2013 Oct 14.


25 Years of AIDS: recording progress and future challenges.

Levy JA, Autran B, Coutinho RA, Phair JP.

AIDS. 2012 Jun 19;26(10):1187-9. doi: 10.1097/QAD.0b013e328354f602. No abstract available.


A frailty-related phenotype before HAART initiation as an independent risk factor for AIDS or death after HAART among HIV-infected men.

Desquilbet L, Jacobson LP, Fried LP, Phair JP, Jamieson BD, Holloway M, Margolick JB.

J Gerontol A Biol Sci Med Sci. 2011 Sep;66(9):1030-8. doi: 10.1093/gerona/glr097. Epub 2011 Jun 30.


CD4+ T-cell counts and plasma HIV-1 RNA levels beyond 5 years of highly active antiretroviral therapy.

Li X, Margolick JB, Jamieson BD, Rinaldo CR, Phair JP, Jacobson LP.

J Acquir Immune Defic Syndr. 2011 Aug 15;57(5):421-8. doi: 10.1097/QAI.0b013e31821e9f21.


Cardiovascular disease in HIV infection.

Palella FJ Jr, Phair JP.

Curr Opin HIV AIDS. 2011 Jul;6(4):266-71. doi: 10.1097/COH.0b013e328347876c. Review.


Association between human immunodeficiency virus infection and stiffness of the common carotid artery.

Seaberg EC, Benning L, Sharrett AR, Lazar JM, Hodis HN, Mack WJ, Siedner MJ, Phair JP, Kingsley LA, Kaplan RC.

Stroke. 2010 Oct;41(10):2163-70. doi: 10.1161/STROKEAHA.110.583856. Epub 2010 Aug 26.


Absence of xenotropic murine leukemia virus-related virus in blood cells of men at risk for and infected with HIV.

Kunstman KJ, Bhattacharya T, Flaherty J, Phair JP, Wolinsky SM.

AIDS. 2010 Jul 17;24(11):1784-5.


Examination of disease-based selection, demographic history and population structure in European Y-chromosome haplogroup I.

Sezgin E, Drosdak A, McIntosh C, Kessing B, Lautenberger JA, Goedert JJ, Phair JP, Troyer JL, Smith MW, O'Brien SJ.

J Hum Genet. 2010 Sep;55(9):613-20. doi: 10.1038/jhg.2010.77. Epub 2010 Jun 24.


The relationship between antibody to R7V and progression of HIV type 1 infection.

Margolick JB, Da Costa Castro JM, Sanchez A, Gemrot F, Phair JP, Jamieson BD, Rinaldo CR, Jacobson LP.

AIDS Res Hum Retroviruses. 2010 Apr;26(4):389-94. doi: 10.1089/aid.2009.0101.


CCL3L1 and HIV/AIDS susceptibility.

Bhattacharya T, Stanton J, Kim EY, Kunstman KJ, Phair JP, Jacobson LP, Wolinsky SM.

Nat Med. 2009 Oct;15(10):1112-5. doi: 10.1038/nm1009-1112. No abstract available.


Fidelity of SNP array genotyping using Epstein Barr virus-transformed B-lymphocyte cell lines: implications for genome-wide association studies.

Herbeck JT, Gottlieb GS, Wong K, Detels R, Phair JP, Rinaldo CR, Jacobson LP, Margolick JB, Mullins JI.

PLoS One. 2009 Sep 4;4(9):e6915. doi: 10.1371/journal.pone.0006915.


Higher risk of AIDS or death in patients with lower CD4 cell counts after virally suppressive HAART.

Taiwo BO, Li X, Palella F, Jacobson LP, Margolick JB, Detels R, Rinaldo CR, Phair JP.

HIV Med. 2009 Nov;10(10):657-60. doi: 10.1111/j.1468-1293.2009.00739.x. Epub 2009 Jul 9.


Relationship between a frailty-related phenotype and progressive deterioration of the immune system in HIV-infected men.

Desquilbet L, Margolick JB, Fried LP, Phair JP, Jamieson BD, Holloway M, Jacobson LP; Multicenter AIDS Cohort Study.

J Acquir Immune Defic Syndr. 2009 Mar 1;50(3):299-306. doi: 10.1097/QAI.0b013e3181945eb0.


Association of Y chromosome haplogroup I with HIV progression, and HAART outcome.

Sezgin E, Lind JM, Shrestha S, Hendrickson S, Goedert JJ, Donfield S, Kirk GD, Phair JP, Troyer JL, O'Brien SJ, Smith MW.

Hum Genet. 2009 Apr;125(3):281-94. doi: 10.1007/s00439-008-0620-7. Epub 2009 Jan 24.


Emergence and persistence of CXCR4-tropic HIV-1 in a population of men from the multicenter AIDS cohort study.

Shepherd JC, Jacobson LP, Qiao W, Jamieson BD, Phair JP, Piazza P, Quinn TC, Margolick JB.

J Infect Dis. 2008 Oct 15;198(8):1104-12. doi: 10.1086/591623.


Effect of tuberculosis on the survival of HIV-infected men in a country with low tuberculosis incidence.

López-Gatell H, Cole SR, Margolick JB, Witt MD, Martinson J, Phair JP, Jacobson LP; Multicenter AIDS Cohort Study.

AIDS. 2008 Sep 12;22(14):1869-73. doi: 10.1097/QAD.0b013e32830e010c.


Detection of HIV-1 p24 Gag in plasma by a nanoparticle-based bio-barcode-amplification method.

Kim EY, Stanton J, Korber BT, Krebs K, Bogdan D, Kunstman K, Wu S, Phair JP, Mirkin CA, Wolinsky SM.

Nanomedicine (Lond). 2008 Jun;3(3):293-303. doi: 10.2217/17435889.3.3.293.


Sexual activity and Kaposi's sarcoma among human immunodeficiency virus type 1 and human herpesvirus type 8-coinfected men.

Nawar EW, Cole SR, Farzadegan H, Witt MD, Jenkins FJ, Margolick JB, Phair JP, Jacobson LP.

Ann Epidemiol. 2008 Jul;18(7):517-21. doi: 10.1016/j.annepidem.2008.03.009. Epub 2008 May 27.


Host genetic influences on highly active antiretroviral therapy efficacy and AIDS-free survival.

Hendrickson SL, Jacobson LP, Nelson GW, Phair JP, Lautenberger J, Johnson RC, Kingsley L, Margolick JB, Detels R, Goedert JJ, O'Brien SJ.

J Acquir Immune Defic Syndr. 2008 Jul 1;48(3):263-71. doi: 10.1097/QAI.0b013e31816fdc5f.


HIV-1 infection is associated with an earlier occurrence of a phenotype related to frailty.

Desquilbet L, Jacobson LP, Fried LP, Phair JP, Jamieson BD, Holloway M, Margolick JB; Multicenter AIDS Cohort Study.

J Gerontol A Biol Sci Med Sci. 2007 Nov;62(11):1279-86.


Prognostic value of HIV-1 RNA, CD4 cell count, and CD4 Cell count slope for progression to AIDS and death in untreated HIV-1 infection.

Mellors JW, Margolick JB, Phair JP, Rinaldo CR, Detels R, Jacobson LP, Muñoz A.

JAMA. 2007 Jun 6;297(21):2349-50. No abstract available.


Estimating the benefit of an HIV-1 vaccine that reduces viral load set point.

Gupta SB, Jacobson LP, Margolick JB, Rinaldo CR, Phair JP, Jamieson BD, Mehrotra DV, Robertson MN, Straus WL.

J Infect Dis. 2007 Feb 15;195(4):546-50. Epub 2007 Jan 5.


Virologic and immunologic response to highly active antiretroviral therapy.

Jacobson LP, Phair JP, Yamashita TE.

Curr HIV/AIDS Rep. 2004 Jun;1(2):74-81. Review.


Use of total lymphocyte count and hemoglobin concentration for monitoring progression of HIV infection.

Lau B, Gange SJ, Phair JP, Riddler SA, Detels R, Margolick JB.

J Acquir Immune Defic Syndr. 2005 Aug 15;39(5):620-5.


Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003.

Seaberg EC, Muñoz A, Lu M, Detels R, Margolick JB, Riddler SA, Williams CM, Phair JP; Multicenter AIDS Cohort Study.

AIDS. 2005 Jun 10;19(9):953-60.


Registration of clinical trials.

Levy JA, Autran B, Coutinho R, Phair JP.

AIDS. 2005 Jan 28;19(2):105. No abstract available.


Prognostic value of plasma HIV RNA among highly active antiretroviral therapy users.

Tarwater PM, Gallant JE, Mellors JW, Gore ME, Phair JP, Detels R, Margolick JB, Muñoz A.

AIDS. 2004 Dec 3;18(18):2419-23.


Update on the Virologic and Immunologic Response to Highly Active Antiretroviral Therapy.

Jacobson LP, Phair JP, Yamashita TE.

Curr Infect Dis Rep. 2004 Aug;6(4):325-332.


A high-density admixture map for disease gene discovery in african americans.

Smith MW, Patterson N, Lautenberger JA, Truelove AL, McDonald GJ, Waliszewska A, Kessing BD, Malasky MJ, Scafe C, Le E, De Jager PL, Mignault AA, Yi Z, De The G, Essex M, Sankale JL, Moore JH, Poku K, Phair JP, Goedert JJ, Vlahov D, Williams SM, Tishkoff SA, Winkler CA, De La Vega FM, Woodage T, Sninsky JJ, Hafler DA, Altshuler D, Gilbert DA, O'Brien SJ, Reich D.

Am J Hum Genet. 2004 May;74(5):1001-13. Epub 2004 Apr 14.


Rapid declines in total lymphocyte counts and hemoglobin concentration prior to AIDS among HIV-1-infected men.

Lau B, Gange SJ, Phair JP, Riddler SA, Detels R, Margolick JB.

AIDS. 2003 Sep 26;17(14):2035-44.


When to initiate highly active antiretroviral therapy: a cohort approach.

Ahdieh-Grant L, Yamashita TE, Phair JP, Detels R, Wolinsky SM, Margolick JB, Rinaldo CR, Jacobson LP.

Am J Epidemiol. 2003 Apr 15;157(8):738-46.


Virologic and immunologic values allowing safe deferral of antiretroviral therapy.

Phair JP, Mellors JW, Detels R, Margolick JB, Muñoz A.

AIDS. 2002 Dec 6;16(18):2455-9.


Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection.

Giorgi JV, Lyles RH, Matud JL, Yamashita TE, Mellors JW, Hultin LE, Jamieson BD, Margolick JB, Rinaldo CR Jr, Phair JP, Detels R; Multicenter AIDS Cohort Study.

J Acquir Immune Defic Syndr. 2002 Apr 1;29(4):346-55.


Virologic and Immunologic Response to Highly Active Antiretroviral Therapy.

Jacobson LP, Phair JP, Yamashita TE.

Curr Infect Dis Rep. 2002 Feb;4(1):88-96.


Evidence of immune reconstitution in antiretroviral drug-experienced patients with advanced HIV disease.

Landay AL, Bettendorf D, Chan E, Spritzler J, Schmitz JL, Bucy RP, Gonzalez CJ, Schnizlein-Bick CT, Evans T, Squires KE, Phair JP.

AIDS Res Hum Retroviruses. 2002 Jan 20;18(2):95-102.


Clinical evaluation and management of metabolic and morphologic abnormalities associated with human immunodeficiency virus.

Wanke CA, Falutz JM, Shevitz A, Phair JP, Kotler DP.

Clin Infect Dis. 2002 Jan 15;34(2):248-59. Epub 2001 Dec 7. Review.


Longitudinal patterns of HIV type 1 RNA among individuals with late disease progression.

Gange SJ, Mellors JW, Lau B, Detels R, Phair JP, Muñoz A, Margolick JB.

AIDS Res Hum Retroviruses. 2001 Sep 1;17(13):1223-9.


Increase and plateau of CD4 T-cell counts in the 3(1/2) years after initiation of potent antiretroviral therapy.

Tarwater PM, Margolick JB, Jin J, Phair JP, Detels R, Rinaldo C, Giorgi J, Muñoz A.

J Acquir Immune Defic Syndr. 2001 Jun 1;27(2):168-75.


Supplemental Content

Loading ...
Support Center